Publication | Open Access

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study

MedicineCancer ManagementGynecologyAdvanced/recurrent Endometrial CancerCancer TreatmentCancer GeneticsOncologyRadiation OncologyGynecology OncologyCancer ResearchNrg Oncology StudyP53 Portends Improvement